Nephrologie / Hypertensiologie 2023 - Prof. Dr. Matthias Girndt und das MARKUS @ HOMe Editorenteam

Im ersten Teil unseres internistischen Jahresrückblicks 2023 präsentieren Prof. Dr. Matthias Girndt (Halle / Saale), Prof. Dr. Marcus Säemann (Wien), Priv.-Doz. Marlies Antlanger (Linz), Prof. Dr. Andreas Kronbichler (Cambridge), Prof. Dr. Dominique Guerrot (Rouen) und Prof. Dr. Gunnar Heine (Frankfurt / Homburg) die zwölf wichtigsten nephrologischen und hypertensiologischen Studien des Jahres 2023.
Das Gespräch wurde am 4.12.2023 geführt.
Weitere Literatur:
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients.
Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A; ESHOL Study Group.
J Am Soc Nephrol 2013
doi: 10.1681/ASN.2012080875
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, Hemels MEW, Huisman MV, Kruip M, Faber LM, Wiersma NM, Buding WF, Fijnheer R, Adriaansen HJ, Roes KC, Hoes AW, Rutten FH, Geersing GJ.
Circulation 2023
doi: 10.1161/CIRCULATIONAHA.123.066485
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002 doi: 10.1001/jama.288.23.2981
Long-term effects of spironolactone in peritoneal dialysis patients.
Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Ohashi H, Ito I, Kasuga H, Horie M, Maruyama S, Yuzawa Y, Matsubara T, Matsuo S; Nagoya Spiro Study Group. J Am Soc Nephrol. 2014
doi: 10.1681/ASN.2013030273
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ.
Lancet 2005
doi: 10.1016/S0140-6736(05)67814-2
Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.
Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N.
J Am Coll Cardiol. 2014
doi: 10.1016/j.jacc.2013.09.056
Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F
J Am Soc Nephrol 2020
doi: 10.1681/ASN.2019060579.
Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. J Am Soc Nephrol. 2021
doi: 10.1681/ASN.2020111566
Severe Hyponatremia Correction, Mortality, and Central Pontine Myelinolysis
Seethapathy H et al.
NEJM Evid 2023
DOI: 10.1056/EVIDoa2300107
A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis.
Genser B, Wanner C, März W.
Eur J Prev Cardiol 2021
doi: 10.1177/2047487320905721
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).
Mancia G et al..
J Hypertens. 2023
doi: 10.1097/HJH.0000000000003480.
Treatment Guidelines for Hyponatremia: Stay the Course.
Sterns RH, Rondon-Berrios H, Adrogué HJ, Berl T, Burst V, Cohen DM, Christ-Crain M, Cuesta M, Decaux G, Emmett M, Garrahy A, Gankam-Kengne F, Hix JK, Hoorn EJ, Kamel KS, Madias NE, Peri A, Refardt J, Rosner MH, Sherlock M, Silver SM, Soupart A, Thompson CJ, Verbalis JG; PRONATREOUS Investigators
Clin J Am Soc Nephrol 2023
doi: 10.2215/CJN.0000000000000244

[@moraxella.catarrhalis]

Tolles Thema, kann's nicht abwarten ^^

[@vladimirshutko1973]

Danke schon!

[@powerfull02101981]

Dannnnnnnnke